Cystic fibrosis

Lancet

Volumn 351, Issue 9098, 1998, Pages 277-282

  Rosenstein, Beryl J ^a,b   Zeitlin, Pamela L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORIDE CHANNEL; CYCLIC AMP; TRANSMEMBRANE CONDUCTANCE REGULATOR;

AUTOSOMAL RECESSIVE INHERITANCE; CHROMOSOME 7; CYSTIC FIBROSIS; GENE MUTATION; GENE THERAPY; GENOTYPE; HUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 0032561983     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)09174-5     Document Type: Review

References (40)

1. 1 Tsui LC. The cystic fibrosis transmembrane conductance regulator gene. Am J Respir Grit Care Med 1995; 151: S47-53.
2. 2 Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989; 245: 1073-80.
3. 3 Stern RC. The diagnosis of cystic fibrosis. N Engl J Med 1997; 336: 487-91.
4. 4 Kant JA, Mifflin TE, McGlennen R, Rixe E, Naylor E, Cooper DL. Molecular diagnosis of cystic fibrosis. Clin Lab Med 1995; 15: 877-98.
5. 5 Knowles MR, Paradiso AM, Boucher RC. In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum Gene Ther 1995;6:445-55.
6. 6 Chillon M, Casals T, Mercier B, et al. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med 1995; 332: 1475-80.
7. 7 Colin AA, Sawyer SM, Mickle JE, Oates RD, Milunsky A, Amos JA. Pulmonary function and clinical observations in men with congenital bilateral absence of the vas deferens. Chest 1996; 110: 440-45.
8. 8 Wilcken B, Wiley V, Sherry G, Bayliss U. Neonatal screening for cystic fibrosis: a comparison of two strategies for case detection in 1-2 million babies. J Pediatr 1995; 127: 965-70.
9. 9 Statement from the National Institutes of Health Workshop on Population Screening for the Cystic Fibrosis Gene. N Engl J Med 1990; 323: 70-71.
10. 10 FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr 1993; 122: 1-9.
11. 11 Konstan MW, Hilliard KA, Norvell TM, Berger M. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 1994; 150: 448-54.
12. 12 Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995; 151: 1075-82.
13. 13 FitzSimmons SC, Burkhart GA, Borowitz D, et al. High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N Engl J Med 1997; 336: 1283-89.
14. 14 Ramsey BW, Dorkin HL, Eisenberg JD, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993; 328: 1740-46.
15. 15 Weaver LT, Green MR, Nicholson K, et al. Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period. Arch Dis Child 1994; 70: 84-89.
16. 16 Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994; 331: 637-42.
17. 17 Trulock EP. Lung transplantation. Am J Respir Crit Care Med 1997; 155: 789-818.
18. 18 Kristidis P, Bozon D, Corey M, et al. Genetic determination of exocrine pancreatic function in cystic fibrosis. Am J Hum Genet 1992; 50: 1178-84.
19. 19 Burke W, Aitken ML, Chen SH, Scott CR. Variable severity of pulmonary disease in adults with identical cystic fibrosis mutations. Chest 1992; 102: 506-09.
20. 20 The Cystic Fibrosis Genotype-Phenotype Consortium. Correlation between genotype and phenotype in patients with cystic fibrosis. N Engl J Med 1993; 329: 1308-13.
21. 21 Gan KH, Veeze HJ, van den Ouweland AM, et al. A cystic fibrosis mutation is associated with mild lung disease. N Engl J Med 1995; 333: 95-99.
22. 22 Kerem E, Rave-Harel N, Augarten A, et al. A cystic fibrosis transmembrane conductance regulator splice variant with partial penetrance associated with variable cystic fibrosis presentations. Am J Respir Crit Care Med 1997; 155: 1914-20.
23. 23 Kunzelmann K, Kiser GL, Schreiber R, Riordan JR. Inhibition of epithelial Na+ currents by intracellular domains of the cystic fibrosis transmembrane conductance regulator. FEBS Lett 1997; 400: 341-44.
24. 24 Schwiebert EM, Egan ME, Hwang TH, et al. CFTR regulates outwardly rectifying chloride channels through an autocrine mechanism involving ATP. Cell 1995; 81: 1063-73.
25. 25 Ward CL, Omura S, Kopito RR. Degradation of CFTR by the ubiquitin-proteosome pathway. Cell 1995; 83: 121-27.
26. 26 Drumm ML, Wilkinson DJ, Smit LS, et al. Chloride conductance expressed by delta F508 and other mutant CFTRs in Xenopus oocytes. Science 1991; 254: 1797-99.
27. 27 Welsh MJ, Denning GM, Ostedgaard LS, Anderson MP. Dysfunction of CFTR being the delta F508 mutation. J Cell Sci 1993; 17 (suppl): 235-39.
28. 28 Cheng SH, Fang SL, Zabner J, et al. Functional activation of the cystic fibrosis trafficking mutant delta F508-CFTR by overexpression. Am J Physiol 1995; 268: L615-24.
29. 29 Smith JJ, Travis SM, Greenberg EP, Welsh MJ. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996; 85: 229-36.
30. 30 Goldman MJ, Anderson GM, Stolzenberg ED, Kari UP, Zasloff M, Wilson JM. Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 1997; 88: 553-60.
31. 31 Howard M, Frizzell RA, Bedwell DM. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med 1996; 2: 467-69.
32. 32 Brown CR, Hong-Brown LQ, Welch WJ. Correcting temperaturesensitive protein folding defects. J Clin Invest 1997; 99: 1432-44.
33. 33 Perrine SP, Ginder GD, Faller DV, et al. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. N Engl J Med 1993; 328: 81-86.
34. 34 Fibach E, Prasanna P, Rodgers GP, Samid D. Enhanced fetal hemoglobin production by phenylacetate and 4-phenylbutyrate in erythroid precursors derived from normal donors and patients with sickle cell anemia and beta-thalassemia. Blood 1993; 82: 2203-09.
35. 35 Kelley TJ, Thomas K, Milgram LJ, Drumm ML. In vivo activation of the cystic fibrosis transmembrane conductance regulator mutant deltaF508 in murine nasal epithelium. Proc Natl Acad Sci USA 1997; 94: 2604-08.
36. 36 Illek B, Fischer H, Santos GF, Widdicombe JH, Machen TE, Reenstra WW. cAMP-independent activation of CFTR C1 channels by the tyrosine kinase inhibitor genistein. Am J Physiol 1995; 268: C886-93.
37. 37 Yang IC, Cheng TH, Wang F, Price EM, Hwang TC. Modulation of CFTR chloride channels by calyculin A and genistein. Am J Physiol 1997; 272: C142-55.
38. 38 Guay-Broder C, Jacobson KA, Barnoy S, et al. Al receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine selectively activates chloride efflux from human epithelial and mouse fibroblast cell lines expressing the cystic fibrosis transmembrane regulator delta F508 mutation. Biochemistry 1995; 34: 9079-87.
39. 39 Johnson LG, Olsen JC, Sarkadi B, Moore KL, Swanstrom R, Boucher RC. Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat Genet 1992; 2: 21-25.
40. 40 Rosenfeld M, Davis R, FitzSimmons S, Pepe M, Ramsey B. Gender gap in cystic fibrosis mortality. Am J Epidemiol 1997; 145: 794-803.